Reuters was ahead of competitors with news that Eli Lilly’s unscheduled trading update revealed lower-than-expected fourth-quarter sales of the weight-loss drug Zepbound, causing the drugmaker’s shares to drop by 8%. This development had a significant impact on the market, highlighting the importance of timely and accurate information in the business and finance sector.
Full Article
Core Labs Posts Flat Revenue in Q2
Core Laboratories (NYSE:CLB), a provider of reservoir optimization and production enhancement services, reported Q2 2025 earnings on July 23, revealing GAAP revenue of $130.2 million, surpassing expectations of $129.1 million, while adjusted EPS of $0.19 met consensus. Although there were operational improvements in international markets, revenue remained largely unchanged year-over-year. Want More Context? 🔎
Read more